

**DESCRIPTION**





<b>Species Reactivity</b>	Human
<b>Specificity</b>	Detects human 4-1BB/TNFRSF9/CD137 in direct ELISAs.
<b>Source</b>	Recombinant Monoclonal Rabbit IgG Clone # 2356B
<b>Purification</b>	Protein A or G purified from cell culture supernatant
<b>Immunogen</b>	Chinese hamster ovary cell line CHO-derived recombinant human 4-1BB/TNFRSF9/CD137 Leu24-His183 Accession # Q07011
<b>Formulation</b>	Lyophilized from a 0.2 µm filtered solution in PBS with Trehalose. See Certificate of Analysis for details. *Small pack size (-SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

**APPLICATIONS**

**Please Note:** Optimal dilutions should be determined by each laboratory for each application. *General Protocols* are available in the *Technical Information* section on our website.

	<b>Recommended Concentration</b>	<b>Sample</b>
<b>Western Blot</b>	2 µg/mL	See Below
<b>Flow Cytometry</b>	0.25 µg/10 <sup>6</sup> cells	See Below
<b>Immunocytochemistry</b>	8-25 µg/mL	See Below
<b>Simple Western</b>	20 µg/mL	HDLM-2 human Hodgkin's lymphoma cells
<b>CyTOF-ready</b>	Ready to be labeled using established conjugation methods. No BSA or other carrier proteins that could interfere with conjugation.	

DATA



PREPARATION AND STORAGE

<b>Reconstitution</b>	Reconstitute at 0.5 mg/mL in sterile PBS.
<b>Shipping</b>	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (-SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
<b>Stability &amp; Storage</b>	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. <ul style="list-style-type: none"> <li>• 12 months from date of receipt, -20 to -70 °C as supplied.</li> <li>• 1 month, 2 to 8 °C under sterile conditions after reconstitution.</li> <li>• 6 months, -20 to -70 °C under sterile conditions after reconstitution.</li> </ul>

## BACKGROUND

4-1BB, also known as CD137 and TNFRSF9, is an approximately 30 kDa transmembrane glycoprotein in the TNF receptor superfamily. 4-1BB functions in the development and activation of multiple immune cells (1). Mature human 4-1BB consists of a 163 amino acid (aa) extracellular domain (ECD) with four TNFR cysteine-rich repeats, a 27 aa transmembrane segment, and a 42 aa cytoplasmic domain (2, 3). Within the ECD, human 4-1BB shares 60% aa sequence identity with mouse and rat 4-1BB. 4-1BB is expressed as a disulfide-linked homodimer on various populations of activated T cell including CD4<sup>+</sup>, CD8<sup>+</sup>, memory CD8<sup>+</sup>, NKT, and regulatory T cells (4-7) as well as on myeloid and mast cell progenitors, dendritic cells, mast cells, and bacterially infected osteoblasts (8-11). It binds with high affinity to the transmembrane 4-1BB Ligand/TNFSF9 which is expressed on antigen presenting cells and myeloid progenitor cells (3, 8). This interaction costimulates the proliferation, activation, and/or survival of the 4-1BB expressing cell (3-7). It can also enhance the activation-induced cell death of repetitively stimulated T cells (3). Mice lacking 4-1BB show augmented T cell activation, perhaps due to its absence on regulatory T cells (12). 4-1BB can associate with OX40 on activated T cells, forming a complex that responds to either ligand and inhibits Treg and CD8<sup>+</sup> T cell proliferation (13). Reverse signaling through 4-1BB Ligand inhibits the development of dendritic cells, B cells, and osteoclasts (8, 11) but supports mature dendritic cell survival and costimulates the proliferation and activation of mast cells (9, 10). 4-1BB activation enhances CD8<sup>+</sup> T cell and NK cell mediated anti-tumor immunity (14). It also contributes to the development of inflammation in high fat diet-induced metabolic syndrome (15). Soluble forms of 4-1BB and 4-1BB Ligand circulate at elevated levels in the serum of rheumatoid arthritis and hematologic cancer patients, respectively (16, 17).

## References:

1. Wang, C. *et al.* (2009) *Immunol. Rev.* **229**:192.
2. Schwarz, H. *et al.* (1993) *Gene* **134**:295.
3. Alderson, M.R. *et al.* (1994) *Eur. J. Immunol.* **24**:2219.
4. Wen, T. *et al.* (2002) *J. Immunol.* **168**:4897.
5. Pulle, G. *et al.* (2006) *J. Immunol.* **176**:2739.
6. Zheng, G. *et al.* (2004) *J. Immunol.* **173**:2428.
7. Kim, D. *et al.* (2008) *J. Immunol.* **180**:2062.
8. Lee, S. *et al.* (2008) *Nat. Immunol.* **9**:917.
9. Choi, B.K. *et al.* (2009) *J. Immunol.* **182**:4107.
10. Nishimoto, H. *et al.* (2005) *Blood* **106**:4241.
11. Saito, K. *et al.* (2004) *J. Biol. Chem.* **279**:13555.
12. Lee, S. *et al.* (2005) *J. Immunol.* **174**:6803.
13. Ma, B.Y. *et al.* (2005) *Blood* **106**:2002.
14. Choi, B.K. *et al.* (2010) *J. Immunol.* **185**:1404.
15. Kim, C. *et al.* (2011) *Diabetes* **60**:3159.
16. Michel, J. *et al.* (1998) *Eur. J. Immunol.* **28**:290.
17. Salih, H.R. *et al.* (2001) *J. Immunol.* **167**:4059.